| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10557-016-6677-Y |
| P698 | PubMed publication ID | 27497930 |
| P50 | author | Doralisa Morrone | Q60687724 |
| P2093 | author name string | Mario Marzilli | |
| Alda Huqi | |||
| Giacinta Guarini | |||
| P2860 | cites work | A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. | Q54503599 |
| 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelin | Q56040237 | ||
| Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 | ||
| Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association | Q22306356 | ||
| Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. | Q24801788 | ||
| Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! | Q26822387 | ||
| Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs | Q28188766 | ||
| Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty | Q28194449 | ||
| Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions | Q28370486 | ||
| The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase | Q28373346 | ||
| Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation | Q28578053 | ||
| Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling | Q33861991 | ||
| Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome | Q33872995 | ||
| Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology | Q33996248 | ||
| Effects of ivabradine and ranolazine in patients with microvascular angina pectoris | Q34337197 | ||
| Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure | Q34530451 | ||
| Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 | ||
| Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 | ||
| A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure | Q34562883 | ||
| Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). | Q34577293 | ||
| Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial | Q34578958 | ||
| Optimal medical therapy with or without PCI for stable coronary disease | Q34612445 | ||
| Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective | Q34623707 | ||
| Regulation of pyruvate dehydrogenase (PDH) activity in human skeletal muscle during exercise | Q34625489 | ||
| Partial fatty acid oxidation inhibitors for stable angina | Q34628656 | ||
| The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure | Q35002505 | ||
| Electrophysiologic basis for the antiarrhythmic actions of ranolazine | Q35091243 | ||
| Anti-anginal and anti-ischemic effects of late sodium current inhibition | Q35147202 | ||
| Cardioprotective effects of trimetazidine: a review | Q35579463 | ||
| Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention | Q35954709 | ||
| Myocardial substrate metabolism in the normal and failing heart | Q36179008 | ||
| Meeting the challenge of chronic ischaemic heart disease with trimetazidine | Q36337459 | ||
| Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation | Q36438849 | ||
| Role of late sodium channel current block in the management of atrial fibrillation | Q36570112 | ||
| Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina | Q36576367 | ||
| Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure | Q37038947 | ||
| Late sodium current inhibition as a new cardioprotective approach | Q37156945 | ||
| Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase | Q37239156 | ||
| A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine | Q37427347 | ||
| Trimetazidine: a meta-analysis of randomised controlled trials in heart failure | Q37816716 | ||
| Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. | Q37871496 | ||
| Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent | Q37909293 | ||
| Rethinking stable ischemic heart disease: is this the beginning of a new era? | Q38041237 | ||
| Therapy against ischemic injury. | Q38070009 | ||
| Pharmacological approaches to coronary microvascular dysfunction. | Q38227301 | ||
| The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials | Q38281542 | ||
| Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI | Q38374426 | ||
| Persistent angina: the Araba Phoenix of cardiology. | Q39293783 | ||
| Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions | Q41387610 | ||
| Biochemical mechanisms of oxfenicine cardiotoxicity | Q42074310 | ||
| Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease | Q42538885 | ||
| The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. | Q42912074 | ||
| B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Corona | Q43124911 | ||
| Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model | Q43156268 | ||
| A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images | Q43243349 | ||
| Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy | Q43741617 | ||
| Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand | Q43811969 | ||
| Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? | Q43872257 | ||
| Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy | Q43995359 | ||
| Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure | Q44112800 | ||
| Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans | Q44200139 | ||
| Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers | Q44270634 | ||
| Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy | Q44365373 | ||
| Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction. | Q44379335 | ||
| Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia | Q44493094 | ||
| Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status | Q44600111 | ||
| Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy | Q44642224 | ||
| Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study | Q45002764 | ||
| Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). | Q45038648 | ||
| Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. | Q45083293 | ||
| Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study | Q45232317 | ||
| Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris | Q45238077 | ||
| Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis | Q45829479 | ||
| Interpreting observational studies of disordered mineral metabolism and mortality in patients on hemodialysis. | Q45911874 | ||
| Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. | Q45922498 | ||
| The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction. | Q46031511 | ||
| The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy | Q46191213 | ||
| Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation | Q46363288 | ||
| A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study | Q46377464 | ||
| Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure | Q46507889 | ||
| The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury | Q46555429 | ||
| Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study | Q46572134 | ||
| Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation | Q46624550 | ||
| Ranolazine inhibits an oxidative stress-induced increase in myocyte sodium and calcium loading during simulated-demand ischemia | Q46656428 | ||
| Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy | Q46713286 | ||
| Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes | Q46715059 | ||
| The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine | Q46803184 | ||
| Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment | Q46814911 | ||
| Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. | Q46819135 | ||
| Trimetazidine protective effect against ischemia-induced susceptibility to ventricular fibrillation in pigs | Q46834471 | ||
| Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study | Q46839232 | ||
| Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits | Q47292092 | ||
| Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks | Q48233485 | ||
| Heart failure in older adults: a conversation with Dr Michael Rich. Interview by Dr Ali Ahmed | Q48553866 | ||
| Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study | Q48569178 | ||
| New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. | Q51291841 | ||
| Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. | Q51579827 | ||
| Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. | Q51661667 | ||
| P433 | issue | 4 | |
| P921 | main subject | stable angina | Q3617336 |
| P304 | page(s) | 379-391 | |
| P577 | publication date | 2016-08-01 | |
| P1433 | published in | Cardiovascular Drugs and Therapy | Q2473050 |
| P1476 | title | Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update | |
| P478 | volume | 30 |
Search more.